For instance, gastrointestinal toxicity is predominant in NSCLC patients treated with anti‐PD‐1/PD‐L1, with subsequent occurrences of endocrine (6.7%–28.8%), musculoskeletal (5.7%–26%) and pulmonary issues (4.4%–23%)23 (Table 1). Here, CD274 is linked to non-small cell lung carcinoma.